Year: 2023

Johnson & Johnson, Astellas Each Sue to Stop Medicare Drug Price Negotiations

July 20, 2023 William Newton, Associate Editor/Senior Writer Views

Johnson & Johnson and Astellas are the latest drugmakers to sue in federal court to stop Medicare drug price negotiation.

Drug manufacturers Johnson & Johnson and Astellas Pharma have each asked federal district courts to strike down parts of the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Expert Tip From Sectyr

July 20, 2023 Sponsored Content Views

Senate Panel Could Mark Up PBM Bill Next Week With Spread Pricing Language That 340B Providers Oppose

July 18, 2023 William Newton, Associate Editor/Senior Writer Views

A group of Republicans on the Senate Finance Committee have called on CMS to withdraw its plan to rewrite the definition of Medicaid best price.

The U.S. Senate Finance Committee could mark up a pharmacy benefit manager reform bill next week with Medicaid managed care [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

U.S. House Energy & Commerce Committee Drafting Drug Shortages Bill

July 18, 2023 Tom Mirga, Editor at Large Views

U.S. House Energy & Commerce Committee Chair Cathy McMorris Rodgers (R-Wash.) says the panel plans to circulate a draft drug shortage bill in the coming weeks.

The U.S. House Energy & Commerce Committee plans to circulate a draft drug shortage bill in the coming weeks, committee [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Judge Rejects 340B Provider Challenge to California Medicaid Drug Payment Shift

July 18, 2023 Rich Daly, Editor in Chief Views

A federal district judge in Sacramento, Calif., dismissed a lawsuit on July 17 aimed at reversing the state’s transfer of Medicaid managed care drugs benefits to Medicaid fee for service.

A federal district judge in Sacramento, Calif., recently dismissed a lawsuit aimed at reversing the state’s January 2022 transfer of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Commentary in NEJM Backs Making Hospitals Report Gross Profits from 340B

July 18, 2023 Tom Mirga, Editor at Large Views

To encourage nonprofit hospitals to do more for their communities, policymakers could examine how hospitals are using their gross profit from the 340B program, an opinion article in The New England Journal of Medicine says.

The 340B drug pricing program has evolved from a “buy low, sell low” program to help safety-net hospitals serve low-income [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Is “Off the Rails,” Civil Rights Leader Chavis Says in Nationally Syndicated Op-Ed

July 18, 2023 Tom Mirga, Editor at Large Views

Health system greed has “made a mockery” of the 340B program, civil rights leader Benjamin Chavis says in nationally syndicated op-ed published by multiple African American news organizations.

Health system greed has “made a mockery” of the 340B drug pricing program and leads to practices that widen health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Medicare Part B Keeping Default Pay Rate for 340B Drugs, Says OPPS Proposed Rule

July 18, 2023 Rich Daly, Editor in Chief Views

Medicare Part B plans to continue paying average sales price plus 6% for for 340B acquired drugs and biologicals in 2024, the U.S. Centers for Medicare & Medicaid Services said July 13.

Medicare Part B plans to continue paying the statutory default rate—generally average sales price plus 6%—for 340B acquired drugs and [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

U.S. Chamber of Commerce Asks Court to Pause Medicare Drug Price Negotiations

July 18, 2023 William Newton, Associate Editor/Senior Writer Views

The U.S. Chamber of Commerce asked a federal district court last week for a preliminary injunction against Medicare drug price negotiation.

The U.S. Chamber of Commerce asked a federal district court in Ohio last week to stop Medicare from implementing the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

In What Could be a First, Drug Maker Gives Providers Deadline to Request 340B Overcharge Refunds

July 13, 2023 Tom Mirga, Editor at Large Views

Drug manufacturer VistaPharm says requests for refunds for 340B overcharges must be received before Aug. 31. No manufacturer is believed to have set such a deadline before, and it's unclear if VistaPharm is the first to say refunds are available upon request.

Generic and over-the-counter drug manufacturer VistaPharm said in a public notice this week that it has identified 340B covered entities [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live